Stock HYPR HYPERFINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hyperfine, Inc.

Equities

HYPR

US44916K1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.879 USD +2.09% Intraday chart for Hyperfine, Inc. -1.58% -21.52%
May. 14 Jefferies Downgrades Hyperfine to Hold From Buy, Price Target is $0.90 MT
May. 13 Transcript : Hyperfine, Inc., Q1 2024 Earnings Call, May 13, 2024

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
HYPERFINE, INC. Stock Hyperfine, Inc.
-21.52% 63.29M -
SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD. Stock Shanghai United Imaging Healthcare Co., Ltd.
-6.98% 14.42B -
IRAY TECHNOLOGY COMPANY LIMITED Stock iRay Technology Company Limited
-42.66% 2.62B
C-
SONOSCAPE MEDICAL CORP. Stock SonoScape Medical Corp.
-14.27% 2.42B -
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Wandong Medical Technology Co.,Ltd.
-16.80% 1.38B - -
CORETAG, INC. Stock Coretag, Inc.
-.--% 1.12B - -
GUERBET Stock Guerbet
+90.26% 507M
B+
NANO-X IMAGING LTD. Stock Nano-X Imaging Ltd.
+32.34% 487M -
DETECTION TECHNOLOGY OYJ Stock Detection Technology Oyj
+27.01% 277M
C
DRTECH CORPORATION Stock DRTECH Corporation
+1.88% 234M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. HYPR Stock
  4. Ratings Hyperfine, Inc.